Research programme: defensin mimetic therapeutics - Innovation Pharmaceuticals

Drug Profile

Research programme: defensin mimetic therapeutics - Innovation Pharmaceuticals

Alternative Names: Arylamide series - PolyMedix; Bactericidal amphiphilic antibiotic compounds - PolyMedix; Calixarene series - PolyMedix; CTIX 1278; CTIX 1502; CTX 1807; Defensin-mimetics - PolyMedix; HDP mimetic compounds - Innovation Pharmaceuticals; Human defense protein mimetics - Innovation Pharmaceuticals; Hydrazide series - PolyMedix; PMX 1408; PMX 1502; PMX 196; PMX 225; PMX 231; PMX 243; PMX-10004; PMX-10033; PMX-10036; PMX-10052; PMX-10056; PMX-10065; PMX-10066; PMX-10067; PMX-10068; PMX-10070; PMX-10072; PMX-10098; PMX-30006; PMX-30016; PMX-30024; PMX-40007; PMX-50003; PMX-519; PMX-60006; PMX-60007; PMX-60014; PMX-70004; PMX-70008; Salicylamide series - PolyMedix

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PolyMedix
  • Developer Innovation Pharmaceuticals
  • Class Calixarenes; Small molecules
  • Mechanism of Action Cell membrane permeability enhancers; Cell membrane structure modulators; Defensin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Acne vulgaris; Gram-negative infections; Proctitis; Rosacea
  • Suspended Anthrax; Hidradenitis suppurativa; Malaria; Tuberculosis
  • No development reported Mycoses

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Mycoses in USA
  • 07 Jun 2017 Cellceutix is now called Innovation Pharmaceuticals
  • 21 Apr 2015 Suspended - Preclinical for Hidradenitis suppurativa in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top